Base de dados : MEDLINE
Pesquisa : D03.383.663.283.266.300 [Categoria DeCS]
Referências encontradas : 4027 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 403 ir para página                         

  1 / 4027 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471519
[Au] Autor:Hughes EL; Becker F; Flower RJ; Buckingham JC; Gavins FNE
[Ad] Endereço:Centre for Brain Sciences, Department of Medicine, Imperial College London, London, W12 0NN, UK.
[Ti] Título:Mast cells mediate early neutrophil recruitment and exhibit anti-inflammatory properties via the formyl peptide receptor 2/lipoxin A receptor.
[So] Source:Br J Pharmacol;174(14):2393-2408, 2017 Jul.
[Is] ISSN:1476-5381
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: In recent years, studies have focused on the resolution of inflammation, which can be achieved by endogenous anti-inflammatory agonists such as Annexin A1 (AnxA1). Here, we investigated the effects of mast cells (MCs) on early LPS-induced neutrophil recruitment and the involvement of the AnxA1-formyl peptide receptor 2/ALX (FPR2/ALX or lipoxin A receptor) pathway. EXPERIMENTAL APPROACH: Intravital microscopy (IVM) was used to visualize and quantify the effects of LPS (10 µg per mouse i.p.) on murine mesenteric cellular interactions. Furthermore, the role that MCs play in these inflammatory responses was determined in vivo and in vitro, and effects of AnxA1 mimetic peptide Ac2-26 were assessed. KEY RESULTS: LPS increased both neutrophil endothelial cell interactions within the mesenteric microcirculation and MC activation (determined by IVM and ruthenium red dye uptake), which in turn lead to the early stages of neutrophil recruitment. MC recruitment of neutrophils could be blocked by preventing the pro-inflammatory activation (using cromolyn sodium) or enhancing an anti-inflammatory phenotype (using Ac2-26) in MCs. Furthermore, MCs induced neutrophil migration in vitro, and MC stabilization enhanced the release of AnxA1 from neutrophils. Pharmacological approaches (such as the administration of FPR pan-antagonist Boc2, or the FPR2/ALX antagonist WRW4) revealed neutrophil FPR2/ALX to be important in this process. CONCLUSIONS AND IMPLICATIONS: Data presented here provide evidence for a role of MCs, which are ideally positioned in close proximity to the vasculature, to act as sentinel cells in neutrophil extravasation and resolution of inflammation via the AnxA1-FPR2/ALX pathway.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Mastócitos/efeitos dos fármacos
Mastócitos/metabolismo
Infiltração de Neutrófilos/efeitos dos fármacos
Receptores de Formil Peptídeo/metabolismo
[Mh] Termos MeSH secundário: Animais
Anexina A1/química
Anexina A1/farmacologia
Anti-Inflamatórios/química
Cromolina Sódica/química
Cromolina Sódica/farmacologia
Células Endoteliais/efeitos dos fármacos
Microscopia Intravital
Lipopolissacarídeos/química
Lipopolissacarídeos/farmacologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Neutrófilos/efeitos dos fármacos
Peptídeos/química
Peptídeos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Annexin A1); 0 (Anti-Inflammatory Agents); 0 (Fpr1 protein, mouse); 0 (Lipopolysaccharides); 0 (Peptides); 0 (Receptors, Formyl Peptide); 0 (annexin A1 peptide (2-26)); 0 (formyl peptide receptor 2, mouse); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bph.13847


  2 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28832739
[Au] Autor:Müller EG; Santos MSD; Freitas D; Gomes JÁP; Belfort R
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo, Brazil.
[Ti] Título:Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.
[So] Source:Arq Bras Oftalmol;80(3):154-158, 2017 Jun.
[Is] ISSN:1678-2925
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the efficacy of monotherapy using tacrolimus eye drops versus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC). METHODS: Randomized double-masked controlled trial comparing the efficacy of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 90 of follow-up. Visual acuity, intraocular pressure, and other complications were evaluated to assess safety and side effects. RESULTS: In total, 16 patients were included, with 8 enrolled in each group. Two patients from Group 2 were excluded from the analysis at days 45 and 90 because of corticosteroid use. Most patients were male (81.8%) and presented with limbal VKC (56.3%). There were statistically significant differences in favor of tacrolimus in the following severity scores: itching at day 90 (p=0.001); foreign body sensation at day 15 (p=0.042); photophobia at day 30 (p=0.041); keratitis at day 30 (p=0.048); and limbal activity at days 15 (p=0.011), 30 (p=0.007), and 45 (p=0.015). No relevant adverse effects were reported, except for a burning sensation with tacrolimus, though this did not compromise treatment compliance. CONCLUSION: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis.
[Mh] Termos MeSH primário: Conjuntivite Alérgica/tratamento farmacológico
Imunossupressores/uso terapêutico
Tacrolimo/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Criança
Conjuntivite Alérgica/patologia
Cromolina Sódica/uso terapêutico
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Soluções Oftálmicas/uso terapêutico
Índice de Gravidade de Doença
Estatísticas não Paramétricas
Fatores de Tempo
Resultado do Tratamento
Acuidade Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Ophthalmic Solutions); Q2WXR1I0PK (Cromolyn Sodium); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE


  3 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28732690
[Au] Autor:Motawi TK; El-Maraghy SA; ElMeshad AN; Nady OM; Hammam OA
[Ad] Endereço:Biochemistry Department, Faculty of Pharmacy, Cairo University, Kasr El Ainy st., Cairo 11562, Egypt. Electronic address: tarek.motawi@pharma.cu.edu.eg.
[Ti] Título:Cromolyn chitosan nanoparticles as a novel protective approach for colorectal cancer.
[So] Source:Chem Biol Interact;275:1-12, 2017 Sep 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Colorectal cancer is the third most common cancer in the world. Cromolyn is a mast cell stabilizer and was proposed as an anticancer agent; however its high polarity limits its bioavailability by rapid washing from the body. We formulated 10 cromolyn chitosan nanoparticles (CCSNPs) following ionic gelation technique to improve its bioavailability and investigated the protective anticancer effect of the optimum formula against colorectal cancer in dimethylhydrazine-induced model in rats. Rats were divided into seven groups, group-1: normal control, group-2: cromolyn control, group-3: CCSNPs control, groups-4 to 7 received dimethylhydrazine for 16 weeks to induce colorectal cancer. Groups-5 to 7 received cromolyn solution, non-medicated chitosan nanoparticles and CCSNPs, respectively as protective treatments. Optimum CCSNPs (size 112.4 nm, charge +39.9 mV, enclosed 93.6% cromolyn and showed a sustained drug release pattern over 48 h) significantly reduced tumor-signaling molecules and the number of aberrant crypt foci compared to dimethylhydrazine. Histopathological examination of colon samples revealed that CCSNPs exerted an augmented protective anticancer effect by ameliorating tumor pathology compared to cromolyn solution. In conclusion, CCSNPs ameliorated tumor pathology and malignant oncogenic signaling molecules in colorectal cancer tissue. Thus, CCSNPs may provide a novel protective approach in colorectal cancer treatment. Moreover, encapsulating cromolyn in chitosan nanoparticles augmented the protective anticancer effect of the drug.
[Mh] Termos MeSH primário: Quitosana/química
Cromolina Sódica/química
Cromolina Sódica/farmacologia
Nanopartículas/química
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/química
Antineoplásicos/farmacologia
Antineoplásicos/uso terapêutico
Neoplasias Colorretais/induzido quimicamente
Neoplasias Colorretais/tratamento farmacológico
Neoplasias Colorretais/patologia
Cromolina Sódica/uso terapêutico
Dimetilidrazinas/toxicidade
Portadores de Fármacos/química
Liberação Controlada de Fármacos
Peroxidação de Lipídeos/efeitos dos fármacos
Masculino
Tamanho da Partícula
Proteínas Proto-Oncogênicas c-akt/metabolismo
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Ratos
Ratos Wistar
Transdução de Sinais/efeitos dos fármacos
beta Catenina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Dimethylhydrazines); 0 (Drug Carriers); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (beta Catenin); 9012-76-4 (Chitosan); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170723
[St] Status:MEDLINE


  4 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28720208
[Au] Autor:Simonsen E; Komenda P; Lerner B; Askin N; Bohm C; Shaw J; Tangri N; Rigatto C
[Ad] Endereço:Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
[Ti] Título:Treatment of Uremic Pruritus: A Systematic Review.
[So] Source:Am J Kidney Dis;70(5):638-655, 2017 Nov.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined. STUDY DESIGN: Systematic review. SETTING & POPULATION: Adult patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. SELECTION CRITERIA FOR STUDIES: PubMed, CINAHL, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov from their inception to March 6, 2017, were systematically searched for randomized controlled trials (RCTs) of uremic pruritus treatments in patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. 2 reviewers extracted data independently. Risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. INTERVENTION: Any intervention for the treatment of uremic pruritus was included. OUTCOMES: A quantitative change in pruritus intensity on a visual analogue, verbal rating, or numerical rating scale. RESULTS: 44 RCTs examining 39 different treatments were included in the review. These treatments included gabapentin, pregabalin, mast cell stabilizers, phototherapy, hemodialysis modifications, and multiple other systemic and topical treatments. The largest body of evidence was found for the effectiveness of gabapentin. Due to the limited number of trials for the other treatments included, we are unable to comment on their efficacy. Risk of bias in most studies was high. LIMITATIONS: Heterogeneity in design, treatments, and outcome measures rendered comparisons difficult and precluded meta-analysis. CONCLUSIONS: Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak. Large, simple, rigorous, multiarm RCTs of promising therapies are urgently needed.
[Mh] Termos MeSH primário: Analgésicos/uso terapêutico
Antiasmáticos/uso terapêutico
Antipruriginosos/uso terapêutico
Fototerapia/métodos
Prurido/terapia
Diálise Renal/métodos
Insuficiência Renal Crônica/complicações
Uremia/complicações
[Mh] Termos MeSH secundário: Administração Cutânea
Aminas/uso terapêutico
Capsaicina/uso terapêutico
Cromolina Sódica/uso terapêutico
Ácidos Cicloexanocarboxílicos/uso terapêutico
Seres Humanos
Falência Renal Crônica/complicações
Falência Renal Crônica/terapia
Pregabalina/uso terapêutico
Prurido/etiologia
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Amines); 0 (Analgesics); 0 (Anti-Asthmatic Agents); 0 (Antipruritics); 0 (Cyclohexanecarboxylic Acids); 55JG375S6M (Pregabalin); 56-12-2 (gamma-Aminobutyric Acid); 6CW7F3G59X (gabapentin); Q2WXR1I0PK (Cromolyn Sodium); S07O44R1ZM (Capsaicin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE


  5 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28114736
[Au] Autor:Ng G; Ohlsson A
[Ad] Endereço:Department of Neonatology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, 5th Floor, Hammersmith House, Du Cane Road, London, UK, W12 0HS.
[Ti] Título:Cromolyn sodium for the prevention of chronic lung disease in preterm infants.
[So] Source:Cochrane Database Syst Rev;1:CD003059, 2017 01 23.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This is an update of a review last published by Cochrane in June 2012 entitled "Cromolyn sodium for the prevention of chronic lung disease in preterm infants", which included two studies. This 2016 update identified no further studies.Chronic lung disease (CLD) frequently occurs in preterm infants and has a multifactorial aetiology including inflammation. Cromolyn sodium is a mast cell stabiliser that inhibits neutrophil activation and neutrophil chemotaxis and therefore may have a role in the prevention of CLD. OBJECTIVES: To determine the effect of prophylactic administration of cromolyn sodium on the incidence of CLD at 28 days or 36 weeks' postmenstrual age (PMA), mortality, or the combined outcome of mortality and CLD at 28 days or 36 weeks' PMA in preterm infants. SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 4), MEDLINE via PubMed (1966 to 12 May 2016), Embase (1980 to 12 May 2016), and CINAHL (1982 to 12 May 2016). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: We included randomised or quasi-randomised controlled clinical trials involving preterm infants. Initiation of cromolyn sodium administration was during the first two weeks of life. The intervention had to include administration of cromolyn sodium by nebuliser or metered dose inhaler with or without spacer device versus placebo or no intervention. Eligible studies had to include at least one of the following outcomes: overall mortality, CLD at 28 days, CLD at 36 weeks' PMA, or the combined outcome mortality and CLD at 28 days. DATA COLLECTION AND ANALYSIS: We used the standard method for Cochrane as described in the Cochrane Handbook for Systematic Reviews of Interventions. We reported risk ratio (RR) and risk difference (RD) with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) with 95% CI for continuous data. The meta-analysis used a fixed-effect model. We examined heterogeneity using the I2 statistic. We assessed the quality of evidence for the main comparison at the outcome level using the GRADE approach. MAIN RESULTS: We identified two eligible studies with small numbers of infants enrolled (64 infants). Prophylaxis with cromolyn sodium did not result in a statistically significant effect on the combined outcome of mortality and CLD at 28 days (typical RR 1.05, 95% CI 0.73 to 1.52; typical RD 0.03, 95% CI -0.20 to 0.27; 2 trials, 64 infants; I2 = 0% for both RR and RD); mortality at 28 days (typical RR 1.31, 95% CI 0.52 to 3.29; I2 = 73% typical RD 0.06, 95% CI -0.13 to 0.26; I2 = 87%; 2 trials, 64 infants) (very low quality evidence); CLD at 28 days (typical RR 0.93, 95% CI 0.53 to 1.64; I2 = 40%; typical RD -0.03, 95% CI -0.27 to 0.20; I2 = 38%; 2 trials, 64 infants) or at 36 weeks' PMA (RR 1.25, 95% CI 0.43 to 3.63; RD 0.08, 95% CI -0.29 to 0.44; 1 trial, 26 infants). There was no significant difference in CLD in survivors at 28 days (typical RR 0.97, 95% CI 0.58 to 1.63; typical RD -0.02, 95% CI -0.29 to 0.26; I2 = 0% for both RR and RD; 2 trials, 50 infants) or at 36 weeks' PMA (RR 1.04, 95% CI 0.38 to 2.87; RD 0.02, 95% CI -0.40 to 0.43; 1 trial, 22 infants). Prophylaxis with cromolyn sodium did not show a statistically significant difference in overall neonatal mortality, incidence of air leaks, necrotising enterocolitis, intraventricular haemorrhage, sepsis, and days of mechanical ventilation. There were no adverse effects noted. The quality of evidence according to GRADE was very low for one outcome (mortality to 28 days) and low for all other outcomes. The reasons for downgrading the evidence was due to design (risk of bias in one study), inconsistency between the two studies (high I2 values for mortality at 28 days for both RR and RD), and lack of precision of estimates (small sample sizes). Further research does not seem to be justified. AUTHORS' CONCLUSIONS: There is currently no evidence from randomised trials that cromolyn sodium has a role in the prevention of CLD. Cromolyn sodium cannot be recommended for the prevention of CLD in preterm infants.
[Mh] Termos MeSH primário: Cromolina Sódica/uso terapêutico
Doenças do Prematuro/prevenção & controle
Pneumopatias/prevenção & controle
Fármacos do Sistema Respiratório/uso terapêutico
[Mh] Termos MeSH secundário: Doença Crônica
Ensaios Clínicos como Assunto
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Doenças do Prematuro/mortalidade
Pneumopatias/mortalidade
Metanálise como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; REVIEW
[Nm] Nome de substância:
0 (Respiratory System Agents); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170411
[Lr] Data última revisão:
170411
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170124
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003059.pub3


  6 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27621136
[Au] Autor:Fathy ME; Abo El Abass Mohamed S; Elmansi H; Belal F
[Ad] Endereço:Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, 35516 Mansoura, Egypt.
[Ti] Título:Simultaneous Determination of Cromolyn Sodium Combined Dosage Forms Using Isocratic HPLC Method.
[So] Source:J Chromatogr Sci;55(1):14-22, 2017 01.
[Is] ISSN:1945-239X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A simple and selective reversed-phase high-performance liquid chromatography method was developed for the estimation of cromolyn sodium (CRM) with either oxymetazoline hydrochloride (OMZ) or xylometazoline hydrochloride (XMZ) in their binary mixtures. The method is based on the simultaneous separation of each drug in a reversed-phase Waters symmetry C18 column (250 mm × 4.6 mm intradermally, 5-µm particle size) at 25°C. Elution was performed with a mobile phase consisting of methanol : 0.1 M phosphate buffer (60:40, v/v, pH 4.0). Quantitation was achieved with ultraviolet detection at 220 nm. The method could determine the three drugs, with linearity, in the range of 2.0-100.0 µg/mL for CRM and 0.8-8.0 µg/mL for OMZ and for XMZ. Aspirin was used as internal standard. Optimization of the separation in terms of mobile phase composition is critical to the method development, which is discussed in detail. The suggested procedure was successfully applied to the analysis of the studied drugs in their nasal preparations. Statistical evaluation of the data obtained by the proposed and comparison methods revealed good accuracy of the proposed method.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Cromolina Sódica/análise
[Mh] Termos MeSH secundário: Cromolina Sódica/química
Combinação de Medicamentos
Imidazóis/análise
Imidazóis/química
Limite de Detecção
Modelos Lineares
Oximetazolina/análise
Oximetazolina/química
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Imidazoles); 8VLN5B44ZY (Oxymetazoline); Q2WXR1I0PK (Cromolyn Sodium); WPY40FTH8K (xylometazoline)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160914
[St] Status:MEDLINE


  7 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28002455
[Au] Autor:Wang X; Liu W; O'Donnell M; Lutgendorf S; Bradley C; Schrepf A; Liu L; Kreder K; Luo Y
[Ad] Endereço:Department of Urology, University of Iowa, Iowa City, Iowa, United States of America.
[Ti] Título:Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study.
[So] Source:PLoS One;11(12):e0168772, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bladder inflammation frequently causes cystitis pain and lower urinary tract dysfunction (LUTD) such as urinary frequency and urgency. Although mast cells have been identified to play a critical role in bladder inflammation and pain, the role of mast cells in cystitis-associated LUTD has not been demonstrated. Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and debilitating inflammatory condition of the urinary bladder characterized by the hallmark symptoms of pelvic pain and LUTD. In this study we investigated the role of mast cells in LUTD using a transgenic autoimmune cystitis model (URO-OVA) that reproduces many clinical correlates of IC/BPS. URO-OVA mice express the membrane form of the model antigen ovalbumin (OVA) as a self-antigen on the urothelium and develop bladder inflammation upon introduction of OVA-specific T cells. To investigate the role of mast cells, we crossed URO-OVA mice with mast cell-deficient KitW-sh mice to generate URO-OVA/KitW-sh mice that retained urothelial OVA expression but lacked endogenous mast cells. We compared URO-OVA mice with URO-OVA/KitW-sh mice with and without mast cell reconstitution in response to cystitis induction. URO-OVA mice developed profound bladder inflammation with increased mast cell counts and LUTD, including increased total number of voids, decreased mean volume voided per micturition, and decreased maximum volume voided per micturition, after cystitis induction. In contrast, similarly cystitis-induced URO-OVA/KitW-sh mice developed reduced bladder inflammation with no mast cells and LUTD detected. However, after mast cell reconstitution URO-OVA/KitW-sh mice restored the ability to develop bladder inflammation and LUTD following cystitis induction. We further treated URO-OVA mice with cromolyn, a mast cell membrane stabilizer, and found that cromolyn treatment reversed bladder inflammation and LUTD in the animal model. Our results provide direct evidence for the role of mast cells in cystitis-associated LUTD, supporting the use of mast cell inhibitors for treatment of certain forms of IC/BPS.
[Mh] Termos MeSH primário: Cistite Intersticial/etiologia
Mastócitos/metabolismo
Dor Pélvica/etiologia
[Mh] Termos MeSH secundário: Animais
Doenças Autoimunes/etiologia
Doenças Autoimunes/imunologia
Doenças Autoimunes/metabolismo
Comportamento Animal/fisiologia
Linfócitos T CD8-Positivos/citologia
Linfócitos T CD8-Positivos/imunologia
Linfócitos T CD8-Positivos/metabolismo
Células Cultivadas
Cromolina Sódica/farmacologia
Cistite Intersticial/imunologia
Cistite Intersticial/metabolismo
Citocinas/genética
Citocinas/metabolismo
Modelos Animais de Doenças
Mastócitos/citologia
Mastócitos/imunologia
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Ovalbumina/imunologia
Dor Pélvica/imunologia
Dor Pélvica/metabolismo
Proteínas Proto-Oncogênicas c-kit/deficiência
Proteínas Proto-Oncogênicas c-kit/genética
RNA Mensageiro/metabolismo
Bexiga Urinária/efeitos dos fármacos
Bexiga Urinária/metabolismo
Bexiga Urinária/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (RNA, Messenger); 9006-59-1 (Ovalbumin); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168772


  8 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27855371
[Au] Autor:Zhang X; Yao H; Qian Q; Li N; Jin W; Qian Y
[Ad] Endereço:Department of Anesthesiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China.
[Ti] Título:Cerebral Mast Cells Participate In Postoperative Cognitive Dysfunction by Promoting Astrocyte Activation.
[So] Source:Cell Physiol Biochem;40(1-2):104-116, 2016.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Astrocytes, the major glial cell type that has been increasingly recognized as contributing to neuroinflammation, are critical in the occurrence and development of postoperative cognitive dysfunction (POCD). Although emerging evidence showed that brain mast cells (MCs) are the "first responders" in neuroinflammation, little is known about the functional communication between MCs and astrocytes. METHODS: In this study, we investigated the potential regulation of astrocyte activation by MCs. Rats received an intracerebroventricular injection of Cromolyn (an MC stabilizer) or sterile saline 30 min before undergoing open tibial fracture surgery, and the levels of neuroinflammation and the degree of memory dysfunction were evaluated at 1 day and 3 days after surgery. In the in vitro study, the effect of activated MCs on astrocytes were further clarified. RESULTS: Surgery increased the number of MCs, the astrocyte activation and the production of inflammatory factors, and resulted in cognitive deficits. Site-directed pre-injection of Cromolyn can inhibit this effect. In the vitro study, the conditioned medium from C48/80-stimulated mast cells (P815) could induce primary astrocyte activation and subsequent production of inflammatory cytokines, which could be inhibited by Cromolyn. CONCLUSION: These findings indicate that activated MCs could trigger astrocyte activation, be involved in neuroinflammation and possibly contribute to POCD. Interactions between MCs and astrocytes could provide potential therapeutic targets for POCD.
[Mh] Termos MeSH primário: Astrócitos/patologia
Cérebro/patologia
Disfunção Cognitiva/patologia
Mastócitos/patologia
Complicações Pós-Operatórias/patologia
[Mh] Termos MeSH secundário: Animais
Astrócitos/efeitos dos fármacos
Contagem de Células
Degranulação Celular/efeitos dos fármacos
Cromolina Sódica/farmacologia
Citocinas/biossíntese
Ativação Enzimática/efeitos dos fármacos
Hipocampo/patologia
Inflamação/patologia
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Masculino
Mastócitos/efeitos dos fármacos
Mastócitos/fisiologia
Ratos Sprague-Dawley
Tíbia/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170213
[Lr] Data última revisão:
170213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161118
[St] Status:MEDLINE


  9 / 4027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27382945
[Au] Autor:Shih HM; Bair MJ; Chen HL; Lin IT
[Ti] Título:Eosinophilic Gastroenteritis : Brief Review.
[So] Source:Acta Gastroenterol Belg;79(2):239-44, 2016 Apr-Jun.
[Is] ISSN:1784-3227
[Cp] País de publicação:Belgium
[La] Idioma:eng
[Ab] Resumo:Eosinophilic gastroenteritis (EGE) is a rare disease which belongs to primary eosinophilic gastrointestinal disorders (primary EGIDs), characterized by an accumulation of eosinophils in the gastrointestinal (GI) tract and is strongly associated with atopy and allergy. The clinical presentations vary depending on the site and depth of eosinophilic intestinal infiltration. Radiology pictures may show irregular thickening of the folds, but these findings can also be present in other conditions like inflammatory bowel disease and lymphoma. The endoscopic appearance is also nonspecific. The definite diagnosis requires biopsy for histological evidence of GI eosinophilic infiltration and clinicians make the diagnosis in correlation with and by exclusion of other possible causes of eosinophilic infiltration. Because EGE is a rare disease, the treatment is based on limited case reports and clinicians' experience. Corticosteroids are the mainstay of therapy. The prognosis of EGE is relatively good when patients receive timely and proper treatment.
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Endoscopia do Sistema Digestório
Enterite/diagnóstico
Eosinofilia/diagnóstico
Gastrite/diagnóstico
Intestino Delgado/patologia
Estômago/patologia
[Mh] Termos MeSH secundário: Acetatos/uso terapêutico
Biópsia
Cromolina Sódica/uso terapêutico
Enterite/tratamento farmacológico
Eosinofilia/tratamento farmacológico
Gastrite/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Seres Humanos
Fatores Imunológicos/uso terapêutico
Imunossupressores/uso terapêutico
Infliximab/uso terapêutico
Intestino Delgado/diagnóstico por imagem
Cetotifeno/uso terapêutico
Antagonistas de Leucotrienos/uso terapêutico
Mercaptopurina/uso terapêutico
Quinolinas/uso terapêutico
Estômago/diagnóstico por imagem
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetates); 0 (Adrenal Cortex Hormones); 0 (Histamine H1 Antagonists); 0 (Immunologic Factors); 0 (Immunosuppressive Agents); 0 (Leukotriene Antagonists); 0 (Quinolines); B72HH48FLU (Infliximab); E7WED276I5 (Mercaptopurine); MHM278SD3E (montelukast); Q2WXR1I0PK (Cromolyn Sodium); X49220T18G (Ketotifen)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160708
[St] Status:MEDLINE


  10 / 4027 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27304487
[Au] Autor:Tong F; Luo L; Liu D
[Ad] Endereço:Department of Chemistry, Medical College, Shantou University, Shantou, China.
[Ti] Título:Effect of Intervention in Mast Cell Function Before Reperfusion on Renal Ischemia-Reperfusion Injury in Rats.
[So] Source:Kidney Blood Press Res;41(3):335-44, 2016.
[Is] ISSN:1423-0143
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Mast cells are sparsely distributed in the kidneys under normal conditions; however, the number of mast cells increases dramatically during renal ischemia/reperfusion injury (RI/RI). When mast cells are stimulated, numerous mediators are released, and under pathological conditions, they produce a wide range of biological effects. The aim of this study was to investigate the effect of intervention in mast cell function before reperfusion on RI/RI. METHODS: Sprague-Dawley (SD) rats (n=50) were randomized into five groups: sham group, ischemia/reperfusion (I/R) group, cromolyn sodium treatment group (CS+I/R group), ketotifen treatment group (K+I/Rgroup), and compound 48/80 treatment group (C+I/R group). I/R injury was induced by bilateral renal artery and vein occlusion for 45 min followed by 24 h of reperfusion. The agents were intravenously administered 5 min before reperfusion through the tail vein. The serum levels of blood urea nitrogen(BUN), serum creatinine (Scr) and histamine and the kidney levels of malondialdehyde (MDA), superoxide dismutase (SOD), tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) were assessed. The expression of intracellular adhesion molecule-1 (ICAM-1) in renal tissue was also measured. RESULTS: I/R injury resulted in severe renal injury, as demonstrated by a large increase in injury scores; serum levels of BUN, Scr and histamine; and kidney levels of MDA, TNF-α, and IL-6; this was accompanied by reduced SOD activity and upregulated ICAM-1 expression. Treatment with cromolyn sodium or ketotifen markedly alleviated I/R-mediated kidney injury, whereas compound 48/80 further aggravated kidney injury. CONCLUSION: Intervention in mast cell activity prior to reperfusionhas a strong effect on RI/RI.
[Mh] Termos MeSH primário: Mastócitos/fisiologia
Traumatismo por Reperfusão/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antialérgicos/administração & dosagem
Antialérgicos/farmacologia
Cromolina Sódica/administração & dosagem
Cromolina Sódica/farmacologia
Cetotifeno/administração & dosagem
Cetotifeno/farmacologia
Rim/lesões
Mastócitos/efeitos dos fármacos
Mastócitos/metabolismo
Ratos
Ratos Sprague-Dawley
Traumatismo por Reperfusão/patologia
Traumatismo por Reperfusão/fisiopatologia
p-Metoxi-N-metilfenetilamina/administração & dosagem
p-Metoxi-N-metilfenetilamina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 4091-50-3 (p-Methoxy-N-methylphenethylamine); Q2WXR1I0PK (Cromolyn Sodium); X49220T18G (Ketotifen)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160616
[St] Status:MEDLINE
[do] DOI:10.1159/000443437



página 1 de 403 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde